GlassScriptPhysician profile
Howard L Friedberg
NPI 1164427696
$3,719.99
in general payments reported to CMS, 2019-2025
30 companies · $636 in 2025
The $636 reported for 2025 was more than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $646 · 2020: $260 · 2021: $450 · 2022: $596 · 2023: $295 · 2024: $836 · 2025: $636.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,767.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,767.40 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $806.97 | 2019-2025 | Clareon, Argos, Total30 |
| Bausch & Lomb Americas INC. | $404.54 | 2022-2025 | Xiidra, Infuse, Miebo |
| Johnson & Johnson Surgical Vision, INC. | $295.12 | 2021-2022 | |
| Aerie Pharmaceuticals, INC. | $233.00 | 2019-2021 | |
| Novartis Pharmaceuticals Corporation | $217.84 | 2019-2022 | |
| Sun Pharmaceutical Industries INC. | $209.69 | 2019-2025 | Cequa |
| Oyster Point Pharma, INC. | $192.60 | 2022-2025 | Tyrvaya |
| Allergan, INC. | $156.51 | 2019-2021 | |
| Tarsus Pharmaceuticals, INC. | $127.24 | 2024-2025 | Xdemvy |
| Carl Zeiss Meditec, INC. | $111.08 | 2019 | |
| Bausch & Lomb, A Division of Bausch Health US, LLC | $107.46 | 2019-2021 | |
| Horizon Therapeutics Plc | $103.25 | 2021-2023 | Tepezza |
| Amgen INC. | $98.18 | 2024-2025 | Tepezza |
| Mallinckrodt Hospital Products INC. | $95.06 | 2021-2022 | |
| Merz Pharmaceuticals, LLC | $74.52 | 2021-2024 | Xeomin |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kala Pharmaceuticals, INC. | $70.24 | 2021-2022 | |
| Merz North America, INC. | $68.73 | 2019-2020 | |
| Rxsight INC | $57.20 | 2023-2024 | Rxsight Injector Handpiece, Rxsight Contact Lens, Rxsight Light Delivery Device (Ldd) |
| Dompe US, INC. | $53.46 | 2021-2025 | Oxervate |
| Abbvie INC. | $48.26 | 2024-2025 | |
| Thea Pharma INC. | $33.29 | 2023-2025 | Iyuzeh |
| Ocular Therapeutix, INC. | $29.34 | 2019-2025 | Dextenza |
| Carl Zeiss Meditec Ag | $19.40 | 2020 | |
| Omeros Corporation | $18.12 | 2019 | |
| Recordati_rare_diseases_inc. | $16.30 | 2022 | |
| Eusa Pharma (US) LLC | $16.29 | 2022 | |
| Eyevance Pharmaceuticals LLC | $15.06 | 2022 | |
| Shire North American Group INC | $14.59 | 2019 | |
| Eyepoint US, INC. | $13.38 | 2019 | |
| Ani Pharmaceuticals, INC. | $13.27 | 2024 | Purified Cortrophin Gel |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Friedberg listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.